Karachi: Drug Regulatory Authority of Pakistan (DRAP) recently issued a notification to recall all the stocks of several medicines posing safety risk to patients. The drugs were termed as ‘ Sub-Standard’ by the regulatory authority.
An official document released by DRAP read that manufacturers should alert their sales officers/suppliers/ distributors to issue instructions to the pharmacies/hospitals, point of sales/purchase/use for the return of suspected stocks of product in question. “Furthermore, you are directed to submit a compliance report of recall to this division within seven (07) days positively,” the notification read.
The medicines recalled due to contamination of glass particles are the following:
|S No.||Generic Name||Drug Name||Manufacturer|
|1||Ibuprofen 200mg/5ml||Torfen Suspension||Kaizen Pharmaceuticals. (Pvt,) Ltd.. Karachi|
|2||diclofenac potassium||Caflam 50mg||GSK Consumer Healthcare Pakistan Limited, Jamshoro|
|3||Azithromycine||Azomax 500mg FCT||GSK Consumer Healthcare Pakistan Limited, Jamshoro|
|4||Paracetamol||Parapals Infusion 1 00ml||Inventor Phama, Karachi.|
|5||Oxiphin||Oxiphin 19 Injection||Kannel Pharmaceuticals, Islamabad|
Earlier, The Drug Regulatory Authority of Pakistan (DRAP), Ministry of National Health Services, Regulations and Coordination, has increased the prices of medicines from 22 to 35 percent yet again within span of one month.